Browse publications on Google Scholar (top-right) ↗
Resume (English only)
Academic Achievements
Past President of the International Society for Pharmacoepidemiology; Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology; Voting consultant to the FDA Drug Safety and Risk Management Advisory Committee; Past inaugural member of the Methods Committee of the Patient-Centered Outcomes Research Institute.
Research Experience
Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine of the Brigham and Women’s Hospital; Professor of Medicine at Harvard Medical School; Professor in Epidemiology at the Harvard T.H. Chan School of Public Health. Principal Investigator of the FDA/CDER-funded Sentinel Innovation Center at Harvard, Duke University, Vanderbilt University, and the University of Washington.
Education
Received medical training at the University of Munich Medical School and masters and doctoral degrees in Pharmacoepidemiology from Harvard.
Background
Studies the comparative effectiveness and safety of biopharmaceuticals and develops methods to reach causal conclusions from analyzing complex healthcare databases. Focuses on newly marketed medications and how real-world evidence can be generated expeditiously at highest quality without compromising the accuracy of findings. Applies data-adaptive algorithms to large healthcare databases to improve confounding control supporting causal inference and calibrates RWE against randomized trials. Disease areas of interest include cardiovascular, antithrombotic therapy, rheumatology, mental health, dermatology, oncology, and others. Teaches courses in principled database analytics in pharmacoepidemiology at Harvard and in Europe.
Miscellany
Current Courses Taught: EPI286 Database Analytics in Pharmacoepidemiology (Fall 2023), EPI253 Effectiveness Research with Longitudinal Healthcare Databases (Summer 2023), AISC 624 Medications and Evidence (October 2022).